Antimicrobial treatment for herpes simplex virus and other infectious diseases

ABSTRACT

An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.

BACKGROUND OF THE INVENTION

[0001] The present invention relates to herpes virus, and moreparticularly, to medical treatments for herpes virus and other microbialinfections.

[0002] Herpes simplex virus (HSV) commonly referred to as “herpes virus”or “herpes,” is an infectious disease which has reached crisisproportions nationally with estimated numbers of infected people at70%-80% of our population as reported by the American Social HealthAssociation (ASHA) and growing annually by 500,000 people or more. Thereare two common types of herpes: herpes simplex virus 1 (HSV 1) andherpes simplex virus 2 (HSV 2).

[0003] Herpes enters the human body through minuscule breaks in theepidermal tissue usually by contact with an infected host and is markedby eruption of one or more vesicles, usually in groups, following anincubation period of approximately four to ten days. Typically thecourse of the infectious outbreak initiates with the prodromal stage;advancing to vesicular eruption; followed by: ulceration; coalescing;resolution; and the latency period. The outbreak can last for severalweeks and on average lasts two-three weeks. In some immune compromisedindividuals the outbreak can last for months. The vesicles can appearanywhere on the skin or mucosa, typically appearing on the lips as coldsores, glands, oral mucosa, conjunctiva and cornea, genitalia, analmucosa and peri-anal tissue.

[0004] Herpes symptoms include: inguinal swelling, pain, fever, malaise,headaches, muscle aches, and swollen glands. Some individuals withtrigeminal nerve affected oral herpes, have excruciating facial pain,difficulty swallowing, eating and facial swelling. Individuals with thesacral nerve effected have severe upper leg pain, swelling, and greatdifficulty walking.

[0005] Herpes simplex virus (HSV) infection is recrudescent, residing inthe nerve ganglia, then recurring due to some, as yet unknown, stimulus.Recurrent herpetic infections can be precipitated by almost anything,including: overexposure to sunlight; nutritional deficiencies; stress,menstruation; immunosuppression; certain foods; drugs; febrile illness;etc. Recently herpes virus was isolated from cardiac tissue.

[0006] HSV 1 and HSV 2 infections pose very serious health threats oftencausing: blindness; increased cancer risk of the cervix; asepticmeningitis and encephalitis; neonatal deaths; viremia; etc. Thedevastating effects of this disease, go well beyond the medical scope ofhuman suffering; HSV is responsible for serious psychological andemotional distress as well as substantial economic loss to the nationand the world.

[0007] Various treatments for herpes have been proposed and haveincluded topical application of such agents as povodoneiodine,idoxuridine, trifluorothymidine, or acyclovir. Such treatments have metwith varying degrees of success. Most prior treatments have provendisappointing. Acyclovir, taken orally for systemic treatment of HSV, issomewhat effective. However, acyclovir is only successful ininterrupting the replication of the virus and is used to treatinfectious outbreak systemically. Nothing to date has proven reallyeffective topically. Strains resistant to acyclovir have been reported.Individuals with Auto Immune Deficiency Syndrome (AIDS) are seriouslyimmune-compromised and suffer especially debilitating outbreaks of HSV.Additionally, AIDS individuals may carry acyclovir resistant strains ofHSV, which can make acyclovir ineffective for these individuals.

[0008] It is, therefore, of utmost importance to develop a safe andsuccessful medical treatment to overcome the very serious problems ofherpes virus.

SUMMARY OF THE INVENTION

[0009] An improved medical treatment and medicine are provided which,when applied in the topical manner, rapidly relieves pain and healslesions of herpes virus. Advantageously, the improved medical treatmentand medicine are safe, inexpensive and effective. The improved medicine,also referred to as Viracea, comprises a novel medical composition,formulation, antimicrobial compound and solution. The new antimicrobialmedical treatment and microbicidal medicine are successful in treatingprimarily herpes simplex virus (HSV 1 & HSV 2) topically and can beuseful in treating other herpes related microbial infections including,but not limited to: varicella zoster virus (herpes zoster) andcytomegalovirus. In some circumstances, it may be useful to use thenovel medicine systemically.

[0010] Advantageously, the improved medical treatment and medicine ofthe present invention yielded unexpected, surprisingly good results.Initial, topical, in vivo testing, demonstrated relief from pain inminutes and speedy total resolution of vesicular eruption in allindividuals tested. When the inventive medical treatment and medicineare applied at the prodromal stage, the infection is interrupted and nofurther outbreak occurs. In vitro testing of the novel medical treatmentand medicine demonstrated extremely surprising inhibitory effects onherpes virus. Desirably, the novel medicine is made from readilyavailable, over the counter (OTC) chemicals or products and provides asafe comfortable, economical and user-friendly treatment.

[0011] While the novel medicine and antimicrobial compound isparticularly useful in dramatically inhibiting herpes virus simplex, itmay be useful in treating other microbial diseases (microbe-causingdiseases)such as: human immunodeficiency virus infection (HIV), Epsteinbarr, papilloma virus, cellulitis, staphylococci, streptococci,mycobacteria, influenza, parainfluenza, adenoviruses, encephalitis,meningitis, arbovirus, arenavirus, anaerobic bacilli, picornavirus,coronavirus and synsytialvirus, as well as varicella zoster virus andcytomegalovirus.

[0012] This easy to use microbicide solution provides a moderately waterresistant coating upon application to either the prodromal tissue or theerythematous vesicular herpes lesion. Upon contact, there is a slighttingling effect. Within minutes of application, the pain of theinfection resolves. Gradually, inguinal swelling subsides, fever,malaise, body aches, and nerve involvement subsides. Typically, withintwenty-one hours all external symptoms and physical manifestations ofinfection are resolved and the vesicle is dried and resolved. Aparticularly surprising, beneficial effect provided by this inventivemedicine, is that when it is applied at the first sign of outbreak, theprodromal stage, all symptoms and signs of further infectious outbreakstops! No eruptions appear or any further escalation of symptoms of theinfection. The outbreak literally stops!

[0013] Desirably, the novel medicine (medical composition) includesmicrobe inhibitors which inhibit, suppress and stop microbial infectionsfrom microbe-causing diseases. The microbe inhibitors compriseantimicrobial isolates, botanical extracts or phytochemicals, of atleast a portion of one or more of the special plants listed below. Themicrobe inhibitors can comprise viral inhibitors to inhibit viraldiseases, such as: herpes simplex virus 1 (HSV 1), herpes virus 2 (HSV2), varicella zoster virus (herpes zoster), cytomegalovirus, HIV,epstein barr, papilloma virus, viral influenza, viral parainfluenza,adenovirus, viral encephalitis, viral menigitus, arbovirus, arenavirus,picornavirus, coronavirus, and synsytialvirus. The microbe inhibitorscan also comprise bacterial inhibitors to inhibit bacterial diseases,such as: cellulitis, staphylococci, streptococci, mycobacteria,bacterial encephalitis, bacterial meningitis, and anaerobic bacilli. Insome circumstances, the microbe inhibitors can include fungi inhibitors.

[0014] Better results are obtained if Echinacea or other plants are notused in the medicine in their raw, untreated and uncut state. For evenbetter results, the medicine can exclude: Arabinose, betaine, cellulose,copper, fructose, fatty acids, galactose, glucose, iron, potassium,protein, resin, sucrose, sulfur, vitamin a, vitamin c, vitamin e andxylose.

[0015] The improved medical treatment provides a novel method andprocess for use in treating the above infectious diseases by applyingthe microbial inhibitors on the microbial infected area and maintainingthe microbe inhibitors on the infected area (region or surface) untilthe external symptoms and physical manifestations of the infectiondisappear, reside or resolve about the infected area. The medicine canbe applied by spraying, dabbing, dusting, swabbing, sponging, brushing,pouring, dispensing, covering, or heavily coating the medicine on themicrobial infected areas, such as: oral mucosa, nasal mucosa, vaginaltissue, labial tissue, anal tissue, peri-anal tissue, lips, cutaneoustissue, sub-cutaneous tissue, ocular tissue, conjunctiva, and eyelids.

[0016] While the medical treatment and medicine is particularly usefulfor inhibiting herpes and other infectious diseases in persons (humanbeings) (homo sapiens), they can also be useful for veterinary purposesfor treating viral and bacterial infections and infectious diseases inanimals, such as: dogs, cats, birds, horses, cows, sheep, swine (pigsand hogs), and other farm animals, as well as rodents and other animalsseen in zoos.

[0017] Preferably, the improved medicine, medical composition ormicrobial compound is a phytochemical concentrate which is combined andsimultaneously or concurrently applied with a surfactant and a carrier,solvent or diluent to provide a microbicide medicinal solution.

[0018] To this end, the interesting microbicide solution comprises anantimicrobial detergent surfactant, with botanical extracts. Thesurfactants preferably are cationic surfactants which can comprisesingly or any number of quaternary ammonium chlorides having 6-18carbons such as alkylbenzyldimethylammonium chloride, mixtures ofalkylbenzyldimethylammonium chloride, alkyldimethyl/ethylbenzylammoniumchloride, n-alkyldimethylbenzylammonium chloride,diisobutylphenoxyethoxyethyldimethylbenzylammonium chloride,N-(C₁₂C₁₄C₁₆) dimethylbenzylammonium chloride, benzalkonium chloride,octyldecyldimethyloammonium chloride, didecyldimethylammonium chloride,dioctyldimethylammonium chloride, dialkyldimethylammonium chloride,dialkylmethylbenzylammonium chloride, octyldecyldimethylammoniumchloride, dimethylbenzylammonium chloride, laurryldimethylbenzylammoniumchloride, o-benzyl-p-chlorophenol, dideryldimethylammonium chloride,doctyldimethylammonium chloride, alkyl (C₁₄C₁₂C₁₆)dimethylbenzylammonium chloride, and preferably comprisesalkylbenzyldimethylammonium chloride most preferably benzalkoniumchloride. The range of activity of the cationic surfactant can be 5% to90% but for best results 8% to 20%. Quaternary ammonium salts arereadily available commercially. In some circumstances it may be usefulto use other surfactants, such as, but not limited to: DMSO, glycolicacid surfactants, enzyme surfactants, ampholytic surfactants,switterionic surfactants, and nonionic surfactants. The surfactants cancomprise detergents, wetting agents, emulsifiers, defoamers, and/orsurface tension reducing additives.

[0019] Carriers are useful for mixing the constituents, keeping theconstituents in solution, and providing an easy method of application tothe affected area whether by spray, dropper, or applicator. While anaqueous solution, preferably a sterile aqueous carrier and solvent ispreferred for best results, in some circumstances it may be desirable touse other liquid or solid carriers, such as: glycerin, mineral oil,silica, cottonseed oil, coconut oil, vegetable oil, seed oil, fish oil,or animal oil, alcohol, talc, corn meal, beeswax, carnauba wax, betacarotene, garlic oil, camphor oil, soluble vitamins, soluble minerals,rape seed oil, nut oils, olive oil, liposomes, ascorbic acid, eveningprimrose oil, pycnogenol, grape seed oil, lanolin, Ethocyn, collagen,aloe vera, bee pollen, royal jelly, chondroitin sulfate A, seavegetables, EDTA, fatty acids, herbs, lecithin, bioflavinoids, grainoils or powders, algae, teas, vinegars, acidophilus, cell salts,ascorbic acids, hydra 5, glandulars, amino acids, psyllium, plantderivatives, or other sterile carriers.

[0020] The botanical extracts antimicrobial isolates or phytochemicalscontained in this new medicine and medical treatment can be comprisedof: Arabinose, betaine, copper, echinacen, echinacin B, echinacoside,echinolone, enzymes, fructose, fatty acids, galactose, glucose,glucuronic acid, inulin, inuloid, iron, pentadecadiene, polyacelylenecompounds, polysaccharides such as but not limited to arabinogalactan,potassium, protein, resin, rhamnose, sucrose, sulfur, tannins, vitaminsa, c, and e, xylose. For better results, the phytochemical concentratesinclude the above phytochemicals, excluding Arabinose, batainecellulose, copper, fructose, fatty acids, galactose, glicose, iron,potassium, protein, resin, sucrose, sulfer, xylose and vitamins a, c ande.

[0021] The botanical extracts, antimicrobial isolates and phytochemicalsare separated, extracted and isolated from portions of plants, such as:pimpinella anisum, myroxylon, arctostaphylos, carum, capsicum, eugeniamytacea, coriandrum, inula, allium, gentiana, juniperus, calendula,origanum, mentha labiate, commiphora, plantago, rosmarinus, ruta,baptisa, artemisa, sage, mentha, parthenium integrifolium, eucalyptus,asteriacea, and preferably from the genus Echinacea of the familyAstericaea, namely, Echinacea purpurea, Echinacea angustofolium,Echinacea pallidae, Echinacea vegetalis, Echinacea atribactilus andtheir cultivars. For best results, the phytochemicals and antimicrobialisolates are extracts from Echinacea purpurea and Echinaceaangustifolium.

[0022] The inventive technology, treatment and medicine yield veryattractive, unexpected, surprisingly good and consistent results. Testsshow the microbicide solution (medicine) and medical treatment to beextremely useful to: heal and control herpes outbreaks, viral shedding,extend the latency periods of the disease, and dramatically inhibit thevirus, while being generally safe to the patient and the environment.

[0023] A more detailed explanation of the invention is provided in thefollowing description and appended claims.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] A herpes virus microbicide and treatment are provided to easepain, heal lesions, resolve infectious outbreaks rapidly and inhibitherpes simplex virus 1 and 2 (HSV 1 & HSV 2). Desirably, the herpesmicrobicide and treatment completely inhibits herpes virus, as well asother infectious microbial diseases, and are safe and non-toxic tohumans, animals, and the environment.

[0025] The herpes microbicide and medicine can comprise a surfactant andan herbaceous botanical providing a botanical extract, phytochemical,antimicrobial isolate, viral isolate, microbe inhibitor, and viralinhibitor. The preferred microbicide composition can comprise: asurfactant; an aqueous diluent; and the herbaceous botanical of thegenus Echinacea (E), of the family Asteracea, species: purpurea,angustifolia, pallidae, vegetalis, atribactilus and the cultivars.Preferably, the herbanaceous botanicals are extracts and isolatescomprising Echinecea phytochemicals as found in and extracted fromEchinacea purpurea, E. pallidae, and E. angustofolia. For best results,the medical treatment and microbicide (medicine) comprises: a cationicsurfactant; the phytochemicals from E. purpurea, and E. angustofolia;and a sterile aqueous diluent.

[0026] The surfactant provides a certain debridement of epithelial cellswith a broad spectrum of antimicrobial action. Surfactants of thisnature can comprise quaternary ammonium salts containing 6-18 carbonatoms. Preferably the quaternary ammonium salt surfactant, is a mixtureof alkyl dimethylbenzylammonium chlorides, which can be: benzalkoniumhalide, benzalkonium bromide, benzalthonium chloride and most preferablybenzalkonium chloride. The herpes treatment comprises a 100% activeaqueous solution but can also be used in concentrate. The solution cancomprise by weight various concentrations of surfactants such as 0.005%to 0.8%, preferably 0.02% to 0.30% and most preferably 0.02% to 0.26%.

[0027] The phytochemicals in the botanical Echinacea have demonstratedimpressive activity against bacteria, viruses, and some fungi. The exactmechanism is unknown. When tested topically in vivo on HSV 1 & 2, it issomewhat effective in treating herpes simplex infectious outbreaks. Whentested in vitro, it showed some inhibitory activity against HSV 1 & 2.

[0028] The phytochemical concentrate composition comprises the followingisolated constituents, botanical extracts, microbial inhibitors, andantimicrobial isolates: polysaccharides, echinacen, echinaceine,echinacoside (caffeic acid ester) echinolone, echinadiol, enzymes,glucuronic acid, inuloid, pentadecadiene, polyacelylene compounds,arabinogalactan, rhamnose, PS I (a 4-0-methylglucoronoarabinoxylan,M_(r) 35 kD) and PS II (an acid rhamnoarabinogalactan, M_(r) 450 kD),cynarin (1,5-di-0-caffeoylquinic acid), acid (2,3-0-di-caffeoyltartaricacid) and derivatives, alkylamides, keto-alkynes and -alkenes; quinones;oils including: borneol, bornyl acetate; pentadeca-8(z)-en-2one,germacrene D, caryophyllene, caryophyllene epoxide, anthocyaninspyrrolizidine alkaloids, lipophilic amides, isobutylamides,polyacetylenes.

[0029] For best results, the antimicrobial isolates of the phytochemicalconcentrate comprise by weight (based upon the total weight of theinventive medical composition): 0.3-9% echinacoside; 0.1-7% PS I (a4-0-methylglucoronoarabinoxylan, M_(r) 35 kD) and PS II (an acidrhamnoarabinogalactan, _(r)M 450 kD); 0.1-10% cynarin(1,5-di-0-caffeoylquinic acid) and acid (2,3-0-di-caffeoyltartaric acid)and derivatives; 0.2-4% echinolone; 0.2-8% echinacin B; 0.1-6%;echinaceine; 0.2-7% anthocyanins comprising cyanidin3-0-β-D-glucopyranoside and 3-0-(6-0-malonyl-β-D-glucopyranoside);0.01-0.06% pyrrolizidine alkaloids comprising tussilagine andisotussilagine; 0.003-0.009% isomeric dodeca isobutylamides and 2E,4E,8Z, 10E/Z-tetraenoic acid; and 0.01-2% caryopylenes.

[0030] The phytochemical concentrate can comprise by weight: 2%-90% ofthe medical composition and solution and preferably comprises not lessthan 15% of the composition and solution; and for best results,comprises 40%-60% of the medical composition and solution.

[0031] The diluent dissolves the benzalkonium chloride (surfactant) andphytochemical concentrates and can act as a carrier in sprays, tubes,and dropper bottles. The preferable diluent is an aqueous diluent andmost preferably is a sterile aqueous diluent. The ratio of water in theaqueous solution to benzalkonium chloride can range from 30,000:1 to250:1 and preferably in topical application from 5000:1 to 750:1. Theratio of water to the combined concentrates of benzalkonium chloride andphytochemicals can comprise a range of 2:1 to 100:1 with a preferablerange of 4:1 to 40:1, and for best results can comprise a ratio of 6:1to 20:1.

[0032] For best results, the improved microbicidal treatment andmedicine (microbicide) for herpes, comprises by weight: 0.02% to 0.3%benzalkonium chloride and to avoid toxicity preferably less than 0.26%;40% to 60% Echinacea phytochemicals; and 20% to 60%, most preferably29.74% to 59.8% sterile water.

[0033] While water is the preferred diluent and carrier, it may bedesirable in some circumstances to use other carriers in order to propelthe concentrate through a sprayer, or for greater solubility andefficacy. It may also be desirable in some circumstances to include aviscosity control agent. Furthermore, while it is estimated that theshelf life of the improved herpes medicine is two years, it may benecessary to add an appropriate preservative.

[0034] For preferred use, during any outbreak or physical manifestationsof herpes and preferably at the first sign of the prodrome stage oftingling, itching, or irritation of herpes, the medical solution(medicine) should be applied topically on the infected area. Theaffected (infected) area should be as dry as possible depending onlocation of outbreak. The method of topical application of medicine canbe by: spraying, dabbing, dropper, or any such method as to coat theentire affected area. The coating of the solution (medicine) should bemaintained until all external symptoms completely resolve, reapplying asneeded anytime the coating diminishes, for instance, after showering.Anionic soaps and anionic detergents, and especially protein contentsoaps can be contraindicated. Preferably, the infected area should bewashed, cleaned and dried prior to application of the medicine.

Clinical Pharmacology

[0035] A preferred surfactant is benzalkonium chloride. Benzalkoniumchloride in aqueous solution is commercially available under the brandname and trade mark Zephiran® distributed by Sanofi WinthropPharmaceuticals (formerly Winthrop Labs). Benzalkonium chloride is arapidly acting anti-infective surfactant with a moderately long durationof action. The surfactant is active against bacteria and some viruses,fungi and protozoa. Bacterial spores are considered to be resistant.Solutions of benzalkonium chloride are bacteriostatic or bacteriocidalaccording to concentration. The exact mechanism of bacterial action ofbenzalkonium chloride is unknown but is thought to be due to enzymeinactivation. Activity of benzalkonium chloride generally increases withincreasing temperature and pH. Gram-positive bacteria are moresusceptible to benzalkonium chloride than gram-negative bacteria.

[0036] Unfortunately, benzalkonium chloride is inactivated by soaps,anionic detergents, serum, and certain proteins. Benzalkonium chloridehas fallen out of favor in many laboratories for the above reasons. Whenbenzalkonium chloride was used alone and tested topically in vivo, itwas ineffective for herpes simplex infectious outbreaks. When tested invitro on HSV1 & 2 benzalkonium chloride demonstrated undesirable highlevels of toxicity to the cells even at high dilutions, which ismedically unacceptable. The chemical formula of one type of benzalkoniumchloride is shown below. Other types of benzalkonium chloride can beused.

Benzalkonium Chloride

[0037]

[0038] While raw, untreated, unprocessed, non-isolated Echinacea isgenerally undesirable to treat herpes, it has been found that some, butnot all, of the isolated constituents and botanical extracts ofEchinacea (as previously described above) provide phytochemicals,antimicrobial isolates, botanical extracts and microbe inhibiters whichare effective in treating herpes virus and other infectious diseases. Aspreviously stated, the phytochemical concentrate composition comprisesthe following isolated constituents, botanical extracts, microbialinhibitors, and antimicrobial isolates: polysaccharides, echinacen,echinaceine, echinacoside (caffeic acid ester), echinolone, echinadiol,enzymes, glucuronic acid, inuloid, pentadecadiene, polyacelylenecompounds, arabinogalactan, rhamnose, PS I (a4-0-methylglucoronoarabinoxylan, M_(r) 35 kD) and PS II (an acidrhamnoarabinogalactan, M_(r) 450 kD), cynarin (1,5-di-0-caffeoylquinicacid), acid (2,3-0-di-caffeoyltartaric acid) and derivatives,alkylamides, keto-alkynes and -alkenes; quinones; oils including:borneol, bornyl acetate; pentadeca-8 (z)-en-2one, germacrene D,caryophyllene, caryophyllene epoxide, anthocyanins pyrrolizidinealkaloids, lipophilic amides, isobutylamides, polyacetylenes. Thechemical formula of some of the botanical extracts of Echinacea areshown below.

[0039] When the Echinacea phytochemicals (antimicrobial isolates,botanical extracts and microbe inhibitors) were mixed, combined andapplied with a surfactant, preferably benzalkonium chloride, and asterile aqueous carrier, the results were unexpected and surprisinglygood in resolving (treating) herpes virus and other infectious diseasesand the effectiveness of the medicine (microbicide) dramaticallyincreased. When the synergistic medicine was tested topically in vivo,the herpes simplex infections were immediately arrested. When thesynergistic medicine was tested in vitro, the benzalkonium chloridesurfactant was substantially less toxic and within a safe level andthere was a higher level of inhibitory activity against HSV 1 & 2. Thesynergism interaction and mixing of the Echinacea phytochemicals andsurfactant were demonstrated and observed by viewing the rapidsolubility of the components when mixed and the slight adhesive qualitycreated by the properties in solution. Furthermore, the chemicalproperties of the Echinacea phytochemicals, surfactant and aqueouscarrier enhanced stabilization and increased reactivity which is usefulin treating infectious diseases.

[0040] The medicine can be used in varying dilutions on: oral and nasalmucosa; vaginal tissue; labial tissue; anal and peri-anal tissue; peniletissue; cutaneous tissue; open subcutaneous tissue; and in higherdilutions on ocular infections. By varying the concentrations, themedicine may possibly be administered parenterally. The medicine may becontraindicated in vaginal or anal packs; in the ear canal; occlusivedressings; casts or ingestion and such use may produce irritation orchemical burns. It may not be advisable to use the medicine to treatanaerobic fungal infections, since some fungi may be resistant.

EXAMPLES 1-7 In Vivo Testing

[0041] In an initial, topical application, in-vivo study that wasundertaken to evaluate the effects of the medical treatment and medicineof the present invention upon seven human test subjects who had beentested positive for HSV 1 or 2. The subjects were treated topically withthe medicine comprising benzalkonium chloride surfactant in an aqueoussolution (at a ratio of 1:750) in combination with the herbaceousbotanical Echinacea purpurea in powdered form containing the previouslylisted phytochemicals. Application of the composition was made by atwo-step procedure by first wetting the affected area or vesicle withthe benzalkonium chloride surfactant in an aqueous solution by spraying,dabbing, or using a dropper; then applying a coating of the powderedphytochemicals over the wetted area by either swab or manuallysprinkling the powder onto the infected area. An important aspect inthis treatment was maintaining complete coverage of the affected areafor the duration of the outbreak. Therefore, the area of outbreak waskept covered with the medical composition by reapplying as needed.

[0042] Of the seven subjects, six were female, and one was male. At thebeginning of this study, the age of the male was 38, the female subjectswere ages 8, 27, 30, 32, 38, and 39. There were twelve infectiousoutbreaks over approximately six weeks. Nine of the outbreaks were HSV2, genital herpes, and three were HSV1, cold sores. The 8 year old andthe 27 year old females exhibited the HSV 1 (cold sores). The 30 yearold, 38 year old and the 39 year old females exhibited the HSV 2(genital herpes). The 38 year old also had a HSV 1 cold sore. The maleexhibited HSV 2 (genital herpes). All subjects tested had a wellestablished history of the disease and could identify the standardcourse of their disease. To obtain objective data, none of the testsubjects knew anything about the test treatment or any action of themedicine. On repeat tests, the subjects were told that there may beplacebos mixed in the samples of formula.

[0043] In seven cases, the antimicrobial compound (medicine) was applieddirectly on tissue at the prodrome stage. In five cases, theantimicrobial compound was applied directly on erupted vesicles. Theantimicrobial compound was reapplied as necessary to maintain coverage.

[0044] Observations:

[0045] With each application of the medicine, each individual (testsubject) reported a tingling sensation for a few seconds. They alsoreported that there was a substantial degree of adherence of themedicine (antimicrobial) compound to the vesicle(s) or affected area.The adherence of the composition to the epithelial tissue remained to adegree even after showering or water rinsing the area.

[0046] Results:

[0047] The results of the testing of the 7 subjects with the medicaltreatment and medicine were unexpectedly surprisingly good and veryconsistent. In each case, the subject happily reported that once thecomposition (medicine) was applied to the affected area, the paincompletely stopped within 10 to 20 minutes when nothing in the past hadever eased pain before. In the seven cases, where the compound(medicine) was applied at the prodrome stage, the subjects reported thatthe pain stopped, all symptoms that would have previously escalated tofull outbreak ceased and the outbreak never occurred. All externalsymptoms and physical manifestations of herpes disappeared within a fewhours after the medicine was applied. In the five cases, where thecompound (medicine) was applied to erupted vesicles, the subjectsreported that the pain stopped in minutes and the burning, itching andirritation resolved in two to four hours and the vesicles dried up andwere gone in twenty-one hours. In all cases, the other more extreme,debilitating symptoms of: fever, malaise, inguinal swelling, weepingsores and painful urination resolved once the medicine was applied.

[0048] In follow-up, where subjects had been given a supply of thecomposition (medicine) to test on future outbreaks, it was reported thatif the initial signs of an outbreak exhibited, signaling the prodromestage of an outbreak, the compound (medicine) was immediately applied bythe subjects as per instructions and the outbreak was fully arrested andfurther symptoms never occurred. Significantly, it was also reported bysubjects who were accustomed to experiencing several outbreaks annually,that they had remarkably longer latency periods. In a three yearfollow-up, one individual who had reported severe outbreaks monthly forfour years prior to use of this medicine, she now reports that she hasnot had an outbreak in over a year since using this medicine.

[0049] Additional Observations:

[0050] One human male subject reported that after the initialapplication during the prodrome phase of an outbreak, he showered andforgot to reapply the composition (medicine) for a period ofapproximately 30 hours. Consequently, several vesicles erupted and beganto coalesce. The subject proceeded to reapply the composition (medicine)and thereafter kept the area well coated with the composition.Subsequently, the outbreak resolved in 21 hours in the same manner asdescribed with the other human subjects.

[0051] Another observation indicated that the composition (medicine) maybe weakened or less effective in the presence of certain proteins orsoaps. One human female subject, may have been overly zealous incleansing the affected area prior to application of the composition(medicine). This occurred during a third outbreak after having successwith the composition (medicine) on two prior outbreaks. In thisinstance, when the composition (medicine) was applied, there was nofamiliar tingling sensation and no relief from symptoms. Approximately24 hours elapsed before she sought any advice and the outbreak hadescalated to the full vesicular eruption stage with all the foregoingsymptoms of the disease. She was instructed to thoroughly rinse any soapresidue from the area, dry the area and reapply the composition(medicine). After following the instructions, she reported that theoutbreak fully resolved, as it had in the two prior outbreaks, afterapplying the medical composition.

EXAMPLES 8-13 Dermatological and Veterinary Testing

[0052] Animal testing to determine any possible dermatological allergicreaction induced by the medical composition (medicine) was undertaken.Six animal subjects were used. The animals included 3 female rabbits(ages unknown); 2 dogs (1 female 2 year old, and 1 male 9 year old);one, 3 year old neutered male cat. In these animal tests, the abovecomposition (medicine) was applied, in the previously stated method, tothe inside of the outer ear of each animal. In all instances, the areabeing treated was kept coated with the compound for twenty-four hours,matching the time human subjects had used. The testing performed on thesix animal subjects indicated that there were no signs of dermatologicalirritation or allergic reaction.

EXAMPLE 14

[0053] The above medical compound containing viral inhibitors was alsotested on a papilloma virus caused wart on the muzzle of a two year oldgelded thoroughbred horse. Papilloma virus warts are difficult to treat.The wart measured 25 mm in diameter. The antimicrobial compound(medicine) was applied twice daily. The wart was then measured at eachapplication.

[0054] Results:

[0055] Quite unexpectedly, the wart decreased dramatically in size byapproximately 3 mm per day while the medicine was applied to the wartand on the fifth day fell off completely. It was observed that, at firstthe surface layers of the wart began to degrade, exposing largeerythematous papules. Then interestingly, the warts did not justdiminish in size by flaking or peeling, they diminished at the point ofattachment on the subject's epidermis and fell off still somewhat intactwith no sequela scarring.

[0056] In an ongoing, long term in vivo study of this invention, whichbegan with the first seven subjects in April of 1989 and has now spanned7 years, approximately 100 infectious outbreaks have been treated withthe medicine in different concentrations, as described previously. Inall cases the surprisingly good results were the same: 1. Paindisappears in minutes; 2. No outbreak occurs when the composition isapplied at the prodrome stage; 3. The outbreak resolves in twenty-onehours when applied at the vesicular stage; 4. Longer latency periods orno further outbreaks.

In Vitro Testing

[0057] Laboratory testing was undertaken at the University Of Chicago,Clinical Microbiology Laboratories to determine inhibitory activity invitro of the medical treatment and composition (medicine). Thelaboratory testing was conducted by the Associate Director, PhD, andAssociate Professor of Pathology. The in vitro testing of the medicalcomposition, referred to as the “Drug” below, yielded surprisingly goodresults. It was determined that the medical treatment and compositionhad unexpectedly, surprising excellent inhibitory activity on HSV 1 andHSV 2. It was stated by the pathologist, that he had tested “hundreds”of other compounds and had never seen anything as good as what thiscompound did.

[0058] The following are the tests of the medicine that were conductedand results that were obtained at The University of Chicago. For ease ofinterpreting some of the scientific data and test results, the followingdefinitions apply:

[0059] “MEM” pertains to Minimal Essential Medium. This is the culturemedium used in laboratories for growing the cells upon which tests willbe run.

[0060] “Fibroblast” is a mesenchyme human cell (a cell found inconnective tissue, blood, bone, lymphatics, and cartilage).

[0061] “IC₅₀” pertains to the Inhibitory Concentrate. For this testing a50% endpoint was selected, as is typical. The number following indicatesthe greatest dilution below 50%. Therefore it is the definition of theendpoint.

[0062] If an area under a dilution is left blank, it indicates thatthere may have been toxicity at that dilution, the test may not havebeen worth reading, or no interpretable data is available.

[0063] If an area under dilution is marked with a hyphen (-), itindicates that there are no plaques and there is total successfulinhibitory activity.

EXAMPLES 15-18

[0064] In these in vitro tests, the following drugs (composition) wasused:

[0065] Drug #1.=Benzalkonium chloride surfactant in an aqueous solutionat a ratio of 1:750. The surfactant in the aqueous solution was filteredbefore use and diluted in an equal volume of 2× MEM to give a 1:1500dilution in 1× MEM.

[0066] Drug #2=Echinacea powder (photochemicals) in an aqueous solution.This preparation was extracted by warm infusion in sterile water. Theextracted phytochemicals was centrifuged and filtered before use. Thefiltered phytochemicals were diluted in an equal volume of 2× MEM togive the undiluted preparation in 1× MEM.

[0067] Drug #3=Echinacea powder (phytochemicals) were extracted andcombined with benzalkonium chloride surfactant by a cold infusionprocess. The combined preparation was centrifuged and filtered beforeuse and diluted in an equal volume of 2× MEM to give the undilutedpreparation in 1× MEM.

[0068] 1. Three 24-compartment plates were inoculated with fibroblasts.Three different extractions (for comparison) in five concentrations ofthe composition were used to screen for antiviral activity inconcentrations of: undiluted, 1:2, 1:4, 1:8, and 1:16 in 1× MEM. Therewere four control compartments on each plate containing MEM withoutdrug.

[0069] 2. The growth media was removed from the compartments and 200 ulof HSV-1 was added to each compartment of the upper half of each plate.HSV-1 was diluted 1:5000 (2.0 ul of stock HSV-1 in 10 mL of MEM). Thevirus titer was 3×10⁶ per mL. Also, 200 ul of HSV-2 was added to eachcompartment of the lower half of each plate. HSV-2 was diluted 1:2,000(5.0 ul of stock HSV-2 in 10 mL of MEM). The virus titer was 6×10⁵ permL.

[0070] 3. The plates were incubated at 37° C. for two hours.

[0071] 4. The inoculum was removed and one mL of the MEM containingDrugs #1-3 were added to the four compartments. The concentration of thedrug compared to the MEM is indicated below. TABLE 1 ConcentrationUndiluted 1:2 1:4 1:8 1:16 Drug (ul) 4000 2000 1000  500  250 MEM (ul) —2000 3000 3500 3750

[0072] 5. Results: HSV-1, liquid overlay, Drug added immediately aftervirus absorption.

[0073] Plate 1, Drug #1 contaminated with bacteria! No growth, maybedebris.

[0074] Plate 2, Drug #2 contaminated with bacteria! No growth, maybedebris.

[0075] Plate 3, Drug #3 The results are indicated in Tables 2 and 3below. TABLE 2 Drug #3 HSV 1 Test Results Concentration undiluted 1:21:4 1:8 1:16 plaques 54 toxic toxic — 6* 12** plaques 42 toxic toxic —4* 16** Average 48 5 14 IC₅₀ > 1:16

[0076] TABLE 3 Drug #3 HSV 2 Test Results Concentration undiluted 1:21:4 1:8 1:16 plaques 46 toxic toxic — 22* 32** plaques 49 toxic toxic —21* 28** Average 48 22 30 IC₅₀ = 1:8

[0077] Comments: Testing with the medicine (Drug #3) provided excellentresults. The cells look fine with no contamination. At the lowerdilutions, the preparation may be toxic to some of the cells. Thispreparation was unexpectedly successful in its inhibitory activity.

EXAMPLES 19-22

[0078] Three 24-compartment plates were inoculated with fibroblasts andthe following drugs.

[0079] Test Drug #1A=Benzalkonium chloride surfactant in an aqueoussolution. The benzalkonium chloride surfactant was prepared by making a1:375 dilution in water (32 ul in 12.0 mL of sterile water). This wasfiltered before use. This was diluted in an equal volume of 2× MEM togive 1:750 dilution in 1× MEM. The dilution was done to maintain theratio.

[0080] Test Drug #2A=Echinacea purpurea powder (phytochemicals)

[0081] in an aqueous solution. This preparation was a 50 mg/mL solution(300 mg in 6.0 mL of water) of Echinacea purpurea powder in sterilewater. The mixture was vortexed and refrigerated for four hours. TheEchinacea powder preparation was centrifuged at 3500 rpm for 15 minutesat 10° C. and filtered before use and then diluted in an equal volume of2× MEM to give the undiluted preparation in 1× MEM.

[0082] Test Drug #3A=Echinacea purpurea powder(phytochemicals)

[0083] dissolved in benzalkonium chloride surfactant. This preparationwas a 50 mg/mL solution (300 mg in 6.0 mL of benzalkonium chloride,1:375). The mixture was vortexed and refrigerated for four hours. Thephytochemical and surfactant mixture was centrifuged at 3500 rpm for 15minutes at 10° C. and filtered before use, and then diluted in an equalvolume of 2× MEM to give the undiluted preparation in 1× MEM.

[0084] 1. Three plates were used to screen the three drug preparations.The concentrations needed to screen for antiviral activity were 1:2,1:4, 1:8, and 1:16 in 1× MEM. There were four control compartments oneach plate containing MEM without drug.

[0085] 2. The growth media was removed from the compartments and 200 ulof HSV-1 was added to each compartment of the upper half of each plate.HSV-1 was diluted 1:5000 (2.0 ul of stock HSV-1 in 10 mL of MEM). Thevirus titer was 3×10⁶ per mL.

[0086] 3. The plates were incubated at 37° C. for four hours.

[0087] 4. The inoculum was removed and one mL of the MEM containingdrugs #1A-3A were added to the four compartments. TABLE 4 ConcentrationUndiluted 1:2 1:4 1:8 1:16 Drug (ul) 4000 2000 1000  500  250 MEN (ul) —2000 3000 3500 3750

[0088] 5. Results: HSV-1, liquid overlay, composition added immediatelyafter virus absorption. TABLE 5 Drug #1A - HSV 1 Test ResultsConcentration 1:2 1:4 1:8 1:16 1:32 plaques 70 toxic toxic toxic toxictoxic plaques 68 plaques 58 plaques 74 Average 70 lC₅₀

[0089] Comments: These compartments have a fine precipitate over thecells. Benzalkonium chloride probably precipitates with the protein inthe medium. TABLE 6 Drug #2A - HSV 1 Test Results Concentration 1:2 1:41:8 1:16 1:32 plaques 72 — — — 9* 12* plaques 74 — — — 7  8 plaques 79 —— — 4 12 plaques 71 — — — 7 11 Average 70 lC₅₀ > 1:32

[0090] Comments: Although there were some plaques, they were very small.TABLE 7 Drug #3A - HSV 1 Test Results Concentration 1:2 1:4 1:8 1:161:32 plaques 72 toxic toxic toxic toxic —* plaques 68 — plaques 67 —plaques 70 — Average 70 lC₅₀ > 1:32

[0091] Comments: Although there was some toxicity, this drug was verysuccessful in inhibiting the virus, there did not appear to be anyplaques.

EXAMPLES 23-27

[0092] Four 24-compartment plates were inoculated with fibroblasts.

[0093] Test Drug #1B=Benzalkonium chloride surfactant in an aqueousdiluent. The benzalkonium chloride was prepared by making a 1:1000dilution in water (10 ul in 10.0 mL of sterile water). This was filteredbefore use and diluted in an equal volume of 2× MEM to give 1:2000dilution in 1× MEM. (500 ul drug plus 500 ul of 2× MEM).

[0094] Test Drug #2B=Echinacea purpurea powder (phytochemicals) in anaqueous solution. This preparation was a 50 mg/mL solution (250 mg in5.0 mL of water) of Echinacea purpurea powder in sterile water. Themixture was vortexed and refrigerated for four hours. This Echinaceapowdered preparation was centrifuged at 3500 rpm for 15 minutes at 10°C. and filtered before use, and diluted in an equal volume of 2× MEM togive the undiluted preparation in 1× MEM. (500 ul drug plus 500 ul of 2×MEM).

[0095] Test Drug #3B =Echinacea purpurea powder (phytochemicals)dissolved in benzalkonium chloride surfactant. This preparation was a 50mg/mL solution (250 mg in 5.0 mL of benzalkonium chloride, 1:1000). Themixture was vortexed and refrigerated for four hours. The Echinaceaphytochemicals and surfactants were centrifuged at 3500 rpm for 15minutes at 10° C. and filtered before use, and then diluted in an equalvolume of 2× MEM to give the preparation in 1× MEM (500 ul drug plus 500ul of 2× MEM).

[0096] Test Drug #4B=Echinacea purpurea powder (phytochemicals) in anaqueous solution (diluent) and then mixed with benzalkonium chloridesurfactant at a ratio of 1:1000. This preparation was a 50 mg/mLsolution (250 mg in 5.0 mL in 5.0 mL of water) of Echinacea purpureapowder in sterile water. The mixture was vortexed and refrigerated forfour hours. The aqueous phytochemicals were centrifuged at 3500 rpm for15 minutes at 10° C. and filtered before use. This preparation wasdiluted in an equal volume of benzalkonium chloride at a ratio of1:1000, to get the Echinacea-benzalkonium chloride mixture. This mixturewas diluted with equal volume of 2× MEM to give the 1:4 preparation in1× MEM (500 ul drug #1 and 250 ul drug #2 plus 500 ul of 2× MEM).

[0097] 1. Four plates were used to screen the four drug preparations.The concentrations needed to screen for antiviral activity were 1:20,1:40, 1:80, and 1:160 and 1:320 in 1× MEM. There were four controlcompartments on each plate containing MEM without drug.

[0098] 2. The growth media was removed from the compartments and 200 ulof HSV-1 was added to each compartment of the upper two rows of eachplate. HSV-1 was diluted 1:5000(2.0 ul of stock HSV-1 in 10 mL of MEM).The virus titer was 3×10⁶ per mL. Also, 200 ul of HSV-2 was added toeach compartment of the lower half of each plate. HSV-2 was diluted1:2,000 (5.0 ul of stock HSV-2 in 10 mL of MEM). The virus titer was6×10⁵ per mL.

[0099] 3. The plates were incubated at 37° C. for four hours.

[0100] 4. The inoculum was removed and one mL of the MEM containingdrugs #1-4 was added to the four compartments. TABLE 8 Concentrate 1:201:40 1:80 1:160 1:320 Drug (ul)  400  200  100  50  25 MEM (ul) 36003800 3900 3950 3975

[0101] 5. Results: HSV-1, liquid overlay, drugs added immediately aftervirus absorption. TABLE 9 Drug #1B - HSV 1 Test Results Concentration1:20 1:40 1:80 1:160 1:320 plaques 37 toxic toxic toxic toxic 15?*plaques 45 18?* Average 41 lC₅₀

[0102] Comments: Slightly toxic, test was difficult to read.

[0103] HSV-2, liquid overlay, drugs added immediately after virusabsorption. TABLE 10 Drug #1B - HSV 2 Test Results Concentration 1:201:40 1:80 1:160 1:320 plaques 38 toxic toxic toxic toxic 21 plaques 4217 Average 40 19 lC₅₀ > 1:320

[0104] Comments: Test was too toxic to give a good reading. TABLE 11Drug #2B - HSV 1 Test Results Concentration 1:20 1:40 1:80 1:160 1:320plaques 39 2*  8* 23* 24 44 plaques 40 3 18 11 28 38 Average 40 3 13 1726 lC₅₀ > 1:80

[0105] Comments: Small plaques. TABLE 12 Drug #2B - HSV 2 Test ResultsConcentration 1:20 1:40 1:80 1:160 1:320 plaques 48 21 33 plaques 52 2238 Average 50 21.5 35.5 lC₅₀ > 1:20

[0106] TABLE 13 Drug #3B - HSV 1 Test Results Concentration 1:20 1:401:80 1:160 1:320 plaques 44 1* 17 31 37 plaques 46 — 16 28 27 Average 45— 17 30 32 lC₅₀ > 1:40

[0107] Comments: Although there was some toxicity, drug very successfulthere did not appear to be any plaques. TABLE 14 Drug #3B - HSV 2 TestResults Concentration 1:20 1:40 1:80 1:160 1:320 few cells 11* 27 30 35plaques 44 10 32 Average 44 11 29.5 lC₅₀ > 1:20

[0108] Comments: A difficult test to get a really good reading. Howeverthe drug has successful inhibitory activity. TABLE 15 Drug #4B - HSV 1Test Results Concentration 1:40 1:80 1:160 1:320 1:640 plaques 47 toxictoxic toxic 33 plaques 48 28 Average 48 30 lC₅₀ > 1:320

[0109] Comments: Too toxic at the higher levels. Nonetheless, there wasinhibitory activity at 1:320 TABLE 16 Drug #4B - HSV 2 Test ResultsConcentration 1:40 1:80 1:160 1:320 1:640 plaques 38 toxic toxic toxic2* 16 plaques 40 4 20 Average 39 3 18 lC₅₀ > 1:640

[0110] Comments: Toxicity probably due to the benzalkonium chloride. Thedrug at the 1:320 dilution showed very strong inhibitory activity.

[0111] The in vitro tests of Examples 23-27 used raw materials whichwere not refined. Nevertheless, the tests demonstrate surprisingly goodviral inhibitory activity and a probable synergy between theconstituents.

[0112] In the preceding in vitro tests where Drugs #3, 3A and 3B, wereEchinacea purpurea phytochemicals extracted and combined withbenzalkonium chloride surfactant, the resultant medicine, demonstratedthe greater antiviral activity, and most remarkably demonstrated asynergy between the components: Echinacea purpurea and benzalkoniumchloride. This can possibly be explained by a shared stability andenhanced reactivity between the two components. The benzalkoniumchloride in the synergistic mixture exhibited a lesser degree oftoxicity and the synergistic combination (medicine) exhibited a greaterdegree of antiviral activity, particularly with HSV-2.

Surfactants

[0113] While benzalkonium chloride is the preferred surfactant for bestresults, in some circumstances it may be desirable to use otherquaternary ammonium surfactants or other surfactants.

[0114] The quaternary ammonium compound can be dicocodimonium chloride,which is also known as dicoco alkyldimethyl, chlorides or dicocodimethyl ammonium chloride or Di-C8-18-alkyldimethyl, chlorides. Thiscan be used in combination with isopropanol, such as 20-30% isopropanol.The preferred source of quaternary compound comprises: 70-80% quaternaryammonium compound and less than 0.03% methyl chloride, has a specificgravity of about 0.87 at 115 degrees F., a vapor pressure of 33 mm/Hg at68 degrees F., an initial boiling point of 180 degrees F. at 760 mm/Hg,and a volatility of 20-30%, and is produced under the brand nameCarSpray 300 by Witco Corporation, Dublin, Ohio, USA. The quaternarycompound can provide disinfecting qualities and serves as a fungicide totreat fungus and yeast infections.

[0115] Other quaternary ammonium compounds may be useful, such asproduced under the brand name Jet Quat 2C-75 by Jetco Chemicals, Inc. ofCorsicana, Texas, USA, or produced under the brand names Carspray 400and Carnauba Spray 200 by Witco Corporation, Dublin, Ohio, USA, orcontaining 9% denatured ethyl alcohol such as sold under the brand nameBTC 2125M by Stephan Company, Northfield, Ill., USA, or the followingMAQUAT products comprising n-alkyl dimethyl benzyl ammonium chlorideproduced by Mason Chemical Company, Arlington Heights, Ill., USA. LC-12S(67% C12, 25% C14, 7% C16, 1% C18), MC 1416 (5% C12, 60% C14, 30% C16,5% C18), MC1412 (40% C12, 50% C14, 10% C16), SC-18 stearyl paste orflake (5% C16, 95% C18), TC-76 or MQ-2525 (5% C12, 60% C14, 30% C16, and5% C18) and MC6025-50% (25% C12, 60% C14 and 15% C16). Jet Quat 2C-75comprises: 50-75% dicoco dimethyl quaternary ammonium chloride, 20-50%isopropyl alcohol, has a specific gravity of 0.88 and a boiling point of180 degrees F. CarSpray 400 comprises: 55-65% quaternary ammoniumcompounds, 20-30% amines, C14-18 & C16-18 unsaturated, alkyl,ethoxylated, 10-20% isopropanol, and less than 0.03% methyl chloride,and has a specific gravity of approximate 0.88 at 75 degrees, F, a vaporpressure of 33 mm/Hg at 68 degrees F., an initial boiling point of 180degrees F. at 760 mm/Hg, and a volatility of 10-20%. Carnauba Spray 200comprises: 50-60% quaternary ammonium compounds, 10-20% isopropanol,15-25% water, 1-10% alkoylated carnauba wax, and less than 0.03% methylchloride, and has a specific gravity of about 0.90 at 80 degrees F., avapor pressure of 33 mm/Hg at 68 degrees F., an initial boiling point of180 degrees F. at 760 mm/Hg, and a volatility of 20-40%.

[0116] Nonionic surfactants are surface-active compounds which do notionize in water solution. Often times these possess hydrophiliccharacteristics by virtue of the presence therein of an oxygenated chain(e.g., a poly-oxyethylene chain), the lyophilic portion of the moleculebeing derived from fatty acids, phenols, alcohols, amides or amines.Exemplary compounds are the poly-(ethylene oxide) condensates of alkylphenols, e.g. the condensation product formed from one mole of nonylphenol and ten moles of ethylene oxide, and the condensation products ofaliphatic alcohols and ethylene oxide, e.g. the condensation productformed from 1 mole of tridecanol and 12 moles of ethylene oxide.

[0117] The nonionic surfactants can comprise phenol ethoxylatescomprising a condensate product of ethylene oxide and an alkyl phenol oran aliphatic alcohol. The nonionic surfactants preferably comprisenonophenol ethoxylate such as T-DET, and/or octaphenol ethoxylate. Thenonionic surfactants are reaction products of ethylene oxide andnonolphenol and/or octalphenol. The ratio of the phenol to the ethyleneoxide can range from 2:20 to 4:16 and preferably is about 8:12.

[0118] Nonionic synthetic surfactants can comprise nonionic detergents.Nonionic synthetic surfactants can also be formed by condensing ethyleneoxide with a hydrophobic base formed by the condensation of propyleneoxide with propylene glycol. The hydrophobic portion of the moleculewhich, of course, exhibits water insolubility has a molecular weight offrom about 1200 to 2500. The addition of polyoxyethylene radicals tothis hydrophobic portion tends to increase the water solubility of themolecule as a whole and the liquid character of the product can beretained up to the point where polyoxyethylene content is about 50% ofthe total weight of the condensation product. Other nonionic syntheticsurfactants can include: the polyethylene oxide condensates ofalkylphenols, e.g. the condensation products of alkylphenols ordialkylphenols wherein the alkyl group contains from about 6 to 12carbon atoms in either a straight chain or branched chain configuration,with ethylene oxide. The ethylene oxide can be present in amounts equalto 8 to 25 moles of ethylene oxide per mole of alkylphenol. The alkylsubstituent in such compounds can be derived from polymerized propylene,diisobutylene, n-octene, or n-nonene.

[0119] Nonionic surfactants can also be produced from the condensationof ethylene oxide with the reaction product of propylene oxide andethylenediamine, e.g. compounds containing from about 40% to about 80%polyoxyethylene by weight and having a molecular weight of from about5,000 to about 11,000 resulting from the reaction of ethylene oxidegroups with a hydrophobic base comprising the reaction product ofethylenediamine and excess propylene oxide; the base having a molecularweight on the order of 2,500 to 3,000.

[0120] Other nonionic surfactants include the condensation product ofaliphatic alcohols having from 8 to 18 carbon atoms, in either straightchain or branched chain configuration, with ethylene oxide, e.g. acoconut alcohol ethylene oxide condensation having from 10 to 30 molesof ethylene oxide per mole of coconut alcohol, and the coconut alcoholfraction having from 10 to 14 carbon atoms.

[0121] Further nonionic surfactants include long chain tertiary amineoxides corresponding to the following general formula:

R₁R₃R₂N→O

[0122] wherein R1 is an alkyl radical of from about 8 to 18 carbonatoms, and R₂ and R₃ are each methyl or ethyl radicals. The arrow in theformula is a conventional representation of a semi-polar bond. Examplesof amine oxides suitable for use include: dimethyldodecylamine oxide,dimethyloctylamine oxide, dimethyldecylamine oxide,dimethyltetradecylamine oxide, and dimethylhexadecylamine oxide.

[0123] Other nonionic surfactants can include: long chain tertiaryphosphine oxides corresponding to the following general formula

RR′R″P→O

[0124] wherein R is an alkyl, alkenyl or monohydroxyalkyl radicalranging from 10 to 18 carbon atoms in chain length and R′ and R″ areeach alkyl or monohydroxyalkyl groups containing from 1 to 3 carbonatoms. The arrow in the formula is a conventional representation of asemi-polar bond. Examples of suitable phosphine oxides are:dimethyldodecylphosphine oxide, dimethyltetradecylphosphine oxide,ethylmethyltetradecylphosphine oxide, cetyldimethylphosphine oxide,dimethylstearylphosphine oxide, cetylethylpropylphosphine oxide,diethyldodecylphosphine oxide, diethyltetradecylphosphine oxide,dipropyldodecylphosphine oxide, bis-(2-hydroxymethyl) dodecylphosphineoxide, bis-(2-hydroxyethyl)dodecylphosphine oxide, (2-hydroxypropyl)methyltetradecylphosphine oxide, dimethyloleylphosphine oxide,and dimethyl-(2-hydroxydodecyl) phosphine oxide.

[0125] In some circumstances it may be useful to use other surfactantssuch as: another cationic surfactant, an ampholytic surfactant or azwitterionic surfactant.

[0126] The cationic surfactants can include cationic detergents. Thecationic surfactants comprise compounds which ionize in an aqueousmedium to give cations containing the lyophilic group. Typical of thesecompounds are the quaternary ammonium salts which contain an alkyl groupof about 12 to about 18 carbon atoms, such as lauryl benzyl dimethylammonium chloride.

[0127] Ampholytic surfactants are compounds having both anionic andcationic groups in the same molecule. Exemplary of such compounds arederivatives of aliphatic amines which contain a long chain of about 8 toabout 18 carbon atoms and an anionic water solubilizing group, e.g.,carboxysulfo, sulfo or sulfato. Examples of ampholytic detergents are:sodium-3-dodecylaminopropane sulfonate, sodium-N-methyl taurate, andrelated substances such as higher alkyl disubstituted amino acids,betaines, thetines, sulfated long chain olefinic amines, and sulfatedimidazoline derivatives.

[0128] Zwitterionic surfactants can include synthetic detergents.Zwitterionic surfactants are generally derivatives of aliphaticquaternary ammonium compounds in which the aliphatic radical can be astraight chain or branched and wherein one of the aliphatic substituentscontains from about 8 to 18 carbon atoms and one contains an anionicwater solubilizing group, e.g., carboxy, sulfo, or sulfato. Examples ofcompounds falling within this definition are:3-(N,N-dimethyl-N-hexadecyl ammonio)-propane-1-sulfonate and3-(N,N-dimethyl-N-hexadecyl ammonio) -2-hydroxy propane-1-sulfonate.

Treatment

[0129] The preferred medical treatment comprises a method for use intreating herpes virus or other infectious diseases by resolving thephysical symptoms of an infectious outbreak of herpes simplex virus 1 or2 (HSV 1 or HSV 2) or other infectious microbial diseases within 1-30hours. This is accomplished by topically applying the above describedpreferred antimicrobial compound (medicine) on the infected area of theherpes simplex virus or other infectious microbial disease, andmaintaining the antimicrobial compound on the infected area for 1-30hours, preferably at least 10 hours. The antimicrobial compound(medicine) can be applied in the manner previously described and mostpreferably coats the infected area. Desirably, the infected area isrinsed (washed) and dried to remove any soap or residue on the infectedarea before the antimicrobial compound (medicine) is applied.Preferably, vesicular eruption of herpes virus are resolved in 19-24hours and herpes lesions are healed by maintaining the above describedmost preferred medicine on the infection for 19-24 hours.

[0130] Among the many advantages of the medical treatment and medicine(compositions) of the invention are:

[0131] 1. Superior results in ending the pain of herpes simplex viralinfections and other microbial infections.

[0132] 2. Outstanding performance in rapidly resolving outbreaks ofherpes simplex virus and other microbial diseases.

[0133] 3. Potentially saves lives of neonates and animals.

[0134] 4. Reduces risk of blindness in newborns.

[0135] 5. Reduces worldwide economic loss from herpes and othermicrobial diseases.

[0136] 6. Resolves the serious emotional and mental anguish of herpessufferers.

[0137] 7. Readily available materials (ingredients).

[0138] 8. Economical.

[0139] 9. Safe.

[0140] 10. Easy to use.

[0141] 11. Dependable.

[0142] 12. Effective.

[0143] Although embodiments of the invention and examples have beenshown and described, it is to be understood that various modificationsand substitutions, as well as rearrangements of parts, components, andprocess steps, methods and treatment, can be made by those skilled inthe art without departing from the novel spirit and scope of thisinvention.

What is claimed is:
 1. A medical composition for use in treatingdiseases, comprising: microbe inhibitors for inhibiting microbialinfections from microbe-causing disease; said microbe inhibitorscomprising antimicrobial isolates of at least a portion of a plantselected from the group consisting of Echinacea purpurea, Echinaceaangustifolia, Echinacea pallidae, Echinacea vegetalis, Echinaceaatribactilus, pimpinella anisum, myroxylon, arctostaphylos, carum,capsicum, eugenia mytacea, coriandrum, inula, allium, gentiana,juniperus, calendula, origanum, mentha labiate, commiphora, plantago,rosmarinus, ruta, laptisa, artemisa, sage, mentha, parthenium,integrifolium, eucalyptus, asteriacea and their cultivars.
 2. A medicalcomposition in accordance with claim 1 wherein: said microbe inhibitorsare selected from the group consisting of viral inhibitors and bacterialinhibitors; said microbe causing-diseases are selected from the groupconsisting of viral diseases and bacterial diseases; said viral diseasesare selected from the group consisting of herpes simplex virus, herpessimplex virus 2, varicella zoster virus (herpes zoster),cytomegalovirus, human immunodeficiency virus, epstein barr, papillomavirus, viral influenza, viral parainfluenza, adenovirus, viralencephalitis, viral meningitis, arbovirus, arenavirus, picornavirus,coronavirus, and synstialvirus; said bacteria diseases are selected fromthe group consisting of cellulitis, staphylococci, streptococcimycobacteria, bacterial encephalitis, bacterial meningitis, andanaerobic bacilli; and said microbe inhibitors are present in saidmedical composition in the absence of raw untreated Echinacea,Arabinose, betaine cellulose, copper, fructose, fatty acids, galactose,glucose, iron, potassium, protein, resin, sucrose, sulfur, vitamin a,vitamin c, vitamin e, and xylose.
 3. A medical composition in accordancewith claim 1 wherein said antimicrobial isolates are selected from thegroup consisting of: echinacen; echinacen B; echinaceine; echinacoside;caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini;inuloid; pentadecadiene; polyacelylene compounds; polysaccharides;arabinogalactan; rhamnose; tannins; PSI (a4-0-methylglucoronoarabinoxylan, Mr 35Kd); PSII (an acidrhamnoarbinogalactan, Mr 450 kD); cynarin; 1,5-di-0-caffeoylquinic acid;acid; 2,3-0-di-caffeoyltartaric acid; borneol; bornyl acetate;pentadeca-8(z)—en-zone; germacrene D; caryophyllene; caryophylleneepoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide;isobutylamide; polyacetylene; anthocyanin; 3-0-B-D-glucopyranoside;3-0-(6-0-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine;isomeric dodeca isobutylamide; tetraenoic acid; carophylenes; andcombinations thereof.
 4. A medical composition for use in treatingherpes virus or other infectious diseases comprising: an antimicrobialcompound comprising at least a portion of a plant selected from thegroup consisting of Echinacea purpurea, Echinacea angustifolia,Echinacea pallidae, Echinacea vegetalis, Echinacea atribactilus andtheir cultivars; and a surfactant.
 5. A medical composition inaccordance with claim 4 wherein: said antimicrobial compound is selectedfrom the group consisting of microbe inhibitors, viral inhibitors,bacterial inhibitors, antimicrobial isolates, botanical extracts, andphytochemicals; and said plant is selected from the group consisting ofEchinacea purpurea, Echinacea angustifolia and Echinacea pallidae.
 6. Amedical composition in accordance with claim 4 wherein: said plant isselected from the group consisting of Echinacea purpurea and Echinaceaangustifolia; and said antimicrobial compound consists of: echinacen;echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone;enzymes; glucuronic acid; inulini; inuloid; pentadecadiene;polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose;tannins; PSI (a 4-0-methylglucoronoarabinoxylan, M_(r) 35 kD) and PS II(an acid rhamnoarabinogalactan, M_(r) 450 kD), cynarin(1,5-di-0-caffeoylquinic acid), acid (2,3-0-di-caffeoyltartaric acid;borneol, bornyl acetate; pentadeca-8(z)-en-zone; germacrene D;caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidinealkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin;3-0-B-D-glucopyranoside; 3-0-(6-0-malonyl-B-D-glucopyranoside);tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoicacid; and carophylenes.
 7. A medical composition in accordance withclaim 4 further including a diluent.
 8. A medical composition inaccordance with claim 7 wherein: said surfactant comprises a cationicsurfactant; and said diluent comprise a sterile aqueous diluent.
 9. Amedical compound in accordance with claim 4 wherein said surfactant isselected from the group consisting of: a cationic surfactant, a nonionicsurfactant, an ampholytic surfactant, a zwitterionic surfactant,quaternary ammonium salt surfactants, a cationic detergent, and aglycolic acid surfacant ant.
 10. A medical compound in accordance withclaim 4 wherein said surfactant comprises a quaternary ammonium saltsurfactant comprising a member selected from the group consisting ofalkyl dimethylbenzylammonium chloride, benzalkonium halide, benzalkoniumbromide, benzathonium chloride, alkylbenzyldimethylammonium chloride,alkyldimethybethylbenzylammonium chloride, n-alkyldimethylbenzylammoniumchloride, diisobutylphenoxyethoxethyl dimethylammonium chloride,n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride,didecyldimethylammonium chloride, dioctyldimethylammonium chloride,diakyldimethylammonium chloride, octyldecylidimethylammonium chloride,laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol,dideryldimethylammonium chloride, doctyldimethylammonium chloride,alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammoniumchloride.
 11. A medical compound in accordance with claim 4 furtherincluding a carrier comprising a member selected from the groupconsisting of: an aqueous carrier, water, glycerin, mineral oil, silica,talc, natural resins, synthetic resins, pyrethrum, tale, thiocyannates,phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seedoil, nut oil, fish oil, animal oil, alcohol, corn meal, beeswax,carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins,soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid,primrose oil, phcynogenol, grape seed oil, lanolin, collagen, herbs,aloe vera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables,fatty acids, lecithin, bioflavinoids, grain oil, grain powder, algae,teas, vinegars, acidophilus, cell salts, glandulars, amino acids,psyllium, plant derivatives, fruit derivates, and a sterile carrier. 12.A medical composition for use in treating herpes virus or otherinfectious diseases, comprising by weight: from about 2% to about 90% ofa phytochemical concentrate of Echinacea purpurea and Echinaceaangustifolia, said phytochemical concentrate comprising antimicrobialisolates selected from the group consisting of: echinacen; echinacen B;echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes;glucuronic acid; inulini; inuloid; pentadecadiene; polyacelylenecompounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a4-0-methylglucoronoarabinoxylan, M_(r) 35Kd); PSII (an acidrhamnoarbinogalactan, M_(r) 450 kD); cynarin; 1,5-di-0-caffeoylquinicacid; acid; 2,3-0-di-caffeoyltartaric acid; borneol; bornyl acetate;pentadeca-8 (z)-en-zone; germacrene D; caryophyllene; caryophylleneepoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide;isobutylamide; polyacetylene; anthocyanin; 3-0-B-D-glucopyranoside;3-0-(6-0-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine;isomeric dodeca isobutylamide; tetraenoic acid; carophylenes; andcombinations thereof; from about 0.005% to about 0.8% quaternaryammonium salt surfactant comprising a member selected from the groupconsisting of alkyl dimethylbenzylammonium chloride, benzalkoniumhalide, benzalkonium bromide, benzathonium chloride,alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammoniumchloride, n-alkyldimethylbenzylammonium chloride,diisobutylphenoxyethoxethyl dimethylammonium chloride,n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride,didecyldimethylammonium chloride, dioctyldimethylammonium chloride,diakyldimethylammonium chloride, octyldecylidimethylammonium chloride,laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol,dideryldimethylammonium chloride, doctyldimethylammonium chloride,alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammoniumchloride; and sterile water providing a diluent and carrier for saidphytochemical concentrate, and the overall ratio of said sterile waterto said phytochemical concentrate and said ammonium salt surfactantranges from about 2:1 to about 100:1.
 13. A medical composition inaccordance with claim 12 wherein said overall ratio ranges from about4:1 to about 40:1.
 14. A medical composition in accordance with claim 12wherein said overall ratio ranges from about 6:1 to about 20:1.
 15. Amedical composition in accordance with claim 12 wherein said ammoniumsalt surfactant comprises benzalkonium chloride and the surfactant ratioof said sterile water to said benzalkonium chloride ranges from about30,000:1 to about 250:1.
 16. A medical composition in accordance withclaim 15 wherein said surfactant ratio ranges from about 5000:1 to about750:1.
 17. A medical composition in accordance with claim 15 whereinsaid medical composition comprises at least 15% phytochemicalconcentrate.
 18. A medical composition in accordance with claim 12comprising by weight: from about 40% to about 60% of said phytochemicalconcentrate; from about 0.02% to about 0.30% ammonium salt surfactantcomprising benzalkonium chloride; and from about 20% to about 60%sterile water.
 19. A medical composition in accordance with claim 18wherein said antimicrobial isolates of said phytochemical concentrate,comprises by weight based upon the total weight of the medicalcomposition: from about 0.3% to about 9% echinacoside; from about 0.1%to about 7% PSI (4-0-methylglucoronoarabinoxylan, M_(r) 35 kD) and PSII(acid rhamnoarabinogalactan, M_(r) 450 kD); from about 0.1% to about 10%cynarin (1,5-di-0-caffeoylquinic acid)and acid(2,3-0-di-caffeoyltartaric acid) and derivatives thereof; from about0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B;from about 0.1 to about 6% echinaceine; from about 2% to about 7%anthonocyanins comprising cynanidin 3-0-B-D-glucopyranoside and3-0-(6-0-malonyl-B-D-glucopyranoside); from about 0.01% to about 0.06%pyrrolizidine alkaloids comprising tussilagine and isotussilagine; fromabout 0.003% to about 0.009% isomeric dodeca isobutyalamides andtetroenoic acid; and from about 0.01% to about 2% caryophylenes.
 20. Amethod for use in treating diseases, comprising the steps of: inhibitingmicrobial infections from microbe-causing diseases by applying microbeinhibitors on a microbial infected region; and maintaining said microbeinhibitors on said infected region until external symptoms and physicalmanifestations of the infection substantially disappear about theinfected region; said microbe inhibitors comprising antimicrobialisolates of at least a portion of a plant selected from the groupconsisting of Echinacea purpurea, Echinacea angustifolia and Echinaceapallidae, Echinacea vegetalis, Echinacea atribactilus, pimpinellaanisum, myroxylon, arctostaphylos, carum, capsicum, eugenia mytacea,coriandrum, inula, allium, gentiana, juniperus, calendula, origanum,mentha labiate, commiphora, plantago, rosmarinus, ruta, laptisa,artemisa, sage, mentha, parthenium, integrifolium, eucalyptus,asteriacea and their cultivars; said microbe inhibitors are selectedfrom the group consisting of viral inhibitors and bacterial inhibitors;said microbe causing-diseases are selected from the group consisting ofviral diseases and bacterial diseases; said viral diseases are selectedfrom the group consisting of herpes simplex virus, herpes simplex virus2, varicella zoster virus (herpes zoster), cytomegalovirus, humanimmunodeficiency virus, epstein barr, papilloma virus, viral influenza,viral parainfluenza, adenovirus, viral encephalitis, viral meningitis,arbovirus, arenavirus, picornavirus, coronavirus, and synstialvirus;said bacteria diseases are selected from the group consisting ofcellulitis, staphylococci, streptocci mycobacteria, bacterialencephalitis, bacterial meningitis, and anaerobic bacilli; and saidmicrobe inhibitors are present in said medical composition in theabsence of raw untreated Echinacea, Arabinose, betaine cellulose,copper, fructose, fatty acids, galactose, glucose, iron, potassium,protein, resin, sucrose, sulfur, vitamin a, vitamin c, vitamin e, andxylose.
 21. A method in accordance with claim 20 wherein: said microbeinhibitors are applied on an external portion of an animal selected fromthe group consisting of a dog, cat, bird, horse, cow, sheep, swine, farmanimal and rodent; and said microbe inhibitors are applied by directlycontacting said infected region of said animal with said microbeinhibitors.
 22. A method in accordance with claim 20 wherein: microbeinhibitors are applied and maintained on an infected region of a homosapien until the external appearance of an eruption and outbreak of saidinfection subside; and said antimicrobial isolates are selected from thegroup consisting of: echinacen; echinacen B; echinaceine; echinacoside;caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini;inuloid; pentadecadiene; polyacelylene compounds; polysaccharides;arabinogalactan; rhamnose; tannins; PSI (a4-0-methylglucoronoarabinoxylan, M_(r) 35Kd); PSII (an acidrhamnoarbinogalactan, M_(r) 450 kD); cynarin; 1,5-di-0-caffeoylquinicacid; chicoric acid; 2,3-0-di-caffeoyltartaric acid; borneol; borneolacetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene;caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilicamide; isobutylamide; polyacetylene; anthocyanin;3-0-B-D-glucopyranoside; 3-0-(6-0-malonyl-B-D-glucopyranoside);tussilagine; isotussilagine; isometric dodeca isobutylamide; tetraenoicacid; carophylenes; and combinations thereof.
 23. A method in accordancewith claim 20 wherein: before said microbe inhibitors are applied, saidinfected region is cleaned and dried; said plant is selected from thegroup consisting of Echinacea purpurea, Echinacea angustifolia,Echinacea pallidae, Echinacea vegetalis, Echinacea atribactilus andtheir cultivars; and said microbe inhibitors are applied concurrentlywith a surfactant.
 24. A method in accordance with claim 20 wherein:said microbe inhibitors are applied simultaneously on the infectedregion with a surfactant and a carrier; said surfactant comprises aquaternary ammonium salt surfactant comprising a member selected fromthe group consisting of alkyl dimethylbenzylammonium chloride,benzalkonium halide, benzalkonium bromide, benzathonium chloride,alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammoniumchloride, n-alkyldimethylbenzylammonium chloride,diisobutylphenoxyethoxethyl dimethylammonium chloride,n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride,didecyldimethylammonium chloride, dioctyldimethylammonium chloride,diakyldimethylammonium chloride, octyldecylidimethylammonium chloride,laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol,dideryldimethylammonium chloride, doctyldimethylammonium chloride,alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammoniumchloride; said carrier comprises a member selected from the groupconsisting of an aqueous carrier, water, glycerin, mineral oil, silica,talc, natural resins, synthetic resins, pyrethrum, tale, thiocyannates,phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seedoil, nut oil, fish oil, animal oil, alcohol, corn meal, beeswax,carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins,soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid,primrose oil, pycnogenol, grape seed oil, lanolin, collagen, herbs, aloevera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables,fatty acids, lecithin, bioflavinoids, grain oil, grain powder, algae,teas, vinegars, acidophilus, cell salts, glandulars, amino acids,psyllium, plant derivatives, fruit derivates, and a sterile carrier. 25.A method for use in treating herpes virus or other infectious diseases,comprising the steps of: substantially resolving the physical symptomsof an infectious outbreak of herpes simplex virus or other infectiousmicrobial diseases within about 1 hours to about 30 hours by topicallyapplying an antimicrobial compound to an infected are of said herpessimplex virus or said other infectious microbial disease; andmaintaining said antimicrobial compound on said infected area for about1 hours to about 30 hours; said antimicrobial compound comprises byweight: from about 2% to about 90% of a phytochemical concentrate ofEchinacea purpurea and Echinacea angustifolia, said phytochemicalconcentrate comprising antimicrobial isolates selected from the groupconsisting antimicrobial isolates selected from the group consisting of:echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester;echinolone; enzymes; glucuronic acid; inulin; inuloid; pentadecadiene;polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose;tannins; PSI (a 4-0-methylglucoronoarabinoxylan, M_(r) 35Kd); PSII (anacid rhamnoarbinogalactain, M_(r) 450 kD); cynarin;1,5-di-0-caffeoylquinic acid; chicoric acid; 2,3-0 di-caffeoyltartaricacid; borneol; borneol acetate; pentadeca-8(z)-en-zone; germacrene D;caryophyllene; caryophyllene epoxide; anthocyanin, pyrolizidinealkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin;3-0-B-D-glucopyranoside; 3-0-(6-0-malonyl-B-D-glucopyranoside);tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoicacid; carophylenes; and combinations thereof; from about 0.005% to about0.8% quaternary ammonium salt surfactant comprising a member selectedfrom the group consisting of alkyl dimethylbenzylammonium chloride,benzalkonium halide, benzalkonium bromide, benzathonium chloride,alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammoniumchloride, n-alkyldimethylbenzylammonium chloride,diisobutylphenoxyethoxethyl dimethylammonium chloride,n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride,didecyldimethylammonium chloride, dioctyldimethylammonium chloride,diakyldimethylammonium chloride, octyldecylidimethylammonium chloride,laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol,dideryldimethylammonium chloride, doctyldimethylammonium chloride,alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammoniumchloride; and sterile water providing a diluent and carrier for saidphytochemical concentrate, and the overall ratio of said sterile waterto said phytochemical concentrate and said ammonium salt surfactantranges from about 2:1 to about 100:1.
 26. A method in accordance withclaim 25 wherein: said infected area is rinsed and dried to remove anysoap or residue on the infected area before said antimicrobial compoundis applied; and said ammonium salt surfactant comprises benzalkoniumchloride and the surfactant ratio of said sterile water to saidbenzalkonium chloride ranges from about 30,000:1 to about 250:1.
 27. Amethod in accordance with claim 25 wherein: said applying is selectedfrom the group consisting of spraying, dabbing, dusting, swabbing,sponging, brushing, pouring, dispensing, covering and coating; and saidinfected area is selected from the group consisting of oral mucosa,nasal mucosa, vaginal tissue, penile tissue, labial tissue, anal tissue,periacinal tissue, lips, cutaneous tissue, sub-cutaneous tissue, oculartissue, conjunctive and eyelids.
 28. A method in accordance with claim25 wherein: vesicular eruption of said herpes simplex virus are resolvedin about 19 hours to about 24 hours by maintaining said antimicrobialcompound on said infected area for about 19 hours to about 24 hours;said herpes simplex virus comprising herpes simplex virus 1 or herpessimplex virus 2; and said antimicrobial compound comprises by weightfrom about 40% to about 60% of said phytochemical concentrate; fromabout 0.02% to about 0.30% ammonium salt surfactant comprisingbenzalkonium chloride; and from about 20% to about 60% sterile water.29. A method in accordance with claim 28 including controlling viralshedding, or healing lesions and extending the latency period of saidherpes virus simplex; and wherein said antimicrobial isolates of saidphytochemical concentrate, comprises by weight based upon the totalweight of the medical composition: from about 0.3% to about 9%echinacoside; from about 0.1% to about 7% PSI(4-0-methylglucoronoarabinoxylan, M_(r) 35 kD) and PSII (acidrhamnoarabinogalactan, M_(r) 450 kD); from about 0.1% to about 10%cynarin (1,5-di-0-caffeoylquinic acid) and chicoric acid(2,3-0-di-caffeoyltartaric acid) and derivatives thereof; from about0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B;from about 0.1 to about 6% echinaceine; from about 2% to about 7%anthonocyanins comprising cynanidin 3-0-B-D-glucopyranoside and3-0-(6-0-malonyl-B-D-glucopyranoside); from about 0.01% to about 0.06%pyrrolizidine alkaloids comprising tussilagine and isotussilagine; fromabout 0.003% to about 0.009% isomeric dodeca isobutyalamides andtetroenoic acid; and from about 0.01% to about 2% caryophylenes.